A5084317346- Cancer Genomics and Diagnostics
- Cancer Cells and Metastasis
- Genetic factors in colorectal cancer
- Cancer Immunotherapy and Biomarkers
- Breast Cancer Treatment Studies
- Epigenetics and DNA Methylation
- Advanced Breast Cancer Therapies
- CAR-T cell therapy research
- Lung Cancer Treatments and Mutations
- RNA modifications and cancer
- Cancer Treatment and Pharmacology
- HER2/EGFR in Cancer Research
- Lung Cancer Diagnosis and Treatment
- BRCA gene mutations in cancer
- MRI in cancer diagnosis
- Immunotherapy and Immune Responses
- Radiomics and Machine Learning in Medical Imaging
- Monoclonal and Polyclonal Antibodies Research
- Cutaneous Melanoma Detection and Management
- Lung Cancer Research Studies
- Effects and risks of endocrine disrupting chemicals
- Cancer-related molecular mechanisms research
- Multiple and Secondary Primary Cancers
- Birth, Development, and Health
- Melanoma and MAPK Pathways
University of California, San Francisco
2022-2025
Northwestern University
2017-2024
UCSF Helen Diller Family Comprehensive Cancer Center
2022-2024
Robert H. Lurie Comprehensive Cancer Center of Northwestern University
2020-2022
Midwestern University
2021-2022
The advent of immunotherapy, particularly immune checkpoint inhibitors (ICIs), has revolutionized the treatment solid tumor malignancies. In breast cancer, most robust data to date for ICI exist triple-negative cancer (TNBC). Preclinical studies suggested increased antitumoral response in patients with TNBC undergoing treatment. Early clinical trials investigated use monotherapy metastatic promising results, first-line setting and those whose tumors had high programmed cell death 1 (PD-1) or...
Abstract Introduction. T-DXd is FDA-approved for patients (pts) with hormone receptor positive (HR+) or HR- HER2-low (IHC 1+ 2+, ISH-) MBC and SG pts HR+/HER2- triple negative MBC. However, several outstanding questions impact the use of these drugs in clinic, including: 1) what efficacy safety agents real-world populations diverse pt characteristics not well represented pivotal phase III trials, 2) sequential treatment ADCs on agents. Methods. In this multicenter retrospective cohort study,...
We describe the genomic landscape of circulating tumour DNA (ctDNA) across pathological subtypes metastatic breast cancer.
OBJECTIVE We used targeted metabolomics in pregnant mothers to compare maternal metabolite associations with BMI, glycemia, and insulin sensitivity. RESEARCH DESIGN AND METHODS Targeted metabolomic assays of clinical metabolites, amino acids, acylcarnitines were performed on fasting 1-h postglucose serum samples from European ancestry, Afro-Caribbean, Thai, Mexican American (400 each ancestry group) who participated the Hyperglycemia Adverse Pregnancy Outcome (HAPO) Study underwent an oral...
Abstract Purpose: Circulating tumor DNA (ctDNA) is a promising tool for noninvasive longitudinal monitoring of genomic alterations. We analyzed serial ctDNA to characterize evolution in progressive metastatic breast cancer. Experimental Design: This was retrospective cohort between 2015 and 2019 obtained under an Institutional Review Board–approved protocol at Northwestern University (Chicago, IL). samples were with Guardant360 next-generation sequencing (NGS) assay. A total 86 patients had...
1083 Background: T-DXd and SG are both FDA-approved treatments for patients (pts) with HER2-low MBC, but little data exists on the sequential use of these ADCs. Methods: In this multicenter retrospective cohort study, we identified pts MBC treated sequentially in either order, or without intervening therapies (IntTx), at 5 academic centers between 2020-2023. We previously reported real-world progression free survival (rwPFS) overall (rwOS) by HR-status ADC sequence order. Here provide...
Abstract Antibody drug conjugates (ADCs) have improved outcomes for patients with metastatic breast cancer (MBC), but there is little data about the sequential use of these agents. In this multicenter retrospective cohort study, we identified 84 HER2-low MBC treated sequentially trastuzumab deruxtecan (T-DXd) and sacituzumab govitecan (SG) in either order at 5 institutions between 2020–2024. We evaluated clinical parameters associated time to treatment failure (TTF) real-world overall...
Abstract Objective Many patients with melanoma treated immune checkpoint inhibitors (ICIs) do not derive response. Preclinical and retrospective studies identified that inhibition of the cyclooxygenase (COX) pathway may improve response to ICI treatment. Methods This prospective single site phase II trial accrued advanced/metastatic melanoma. Participants underwent high-dose aspirin daily combined pembrolizumab ipilimumab every 3 weeks for 4 cycles followed by monotherapy. The primary...
TPS9595 Background: Immune checkpoint inhibitors (ICI) have greatly improved outcomes for patients by targeting programmed cell death protein 1 (PD1), cytotoxic T-lymphocyte–associated antigen 4 (CTLA4) and Lymphocyte Activation Gene-3 (LAG-3) to increase immune-mediated anti-tumor response. Despite these advances, ~50% of with metastatic melanoma do not respond standard care ICI. We strive address this unmet clinical need through a Phase Ib/II, first-in-human, multi-center trial two...
Roughly one third of new non-small cell lung cancer (NSCLC) is diagnosed at early stages. While lobectomy can improve mortality in this group, about 30-55% patients will experience disease recurrence. Increased investigation into the factors affecting recurrence, particularly tumor molecular genetics such as EGFR mutations, needed.We conducted a single-center retrospective study 282 with or locally advanced adenocarcinoma, without who underwent definitive therapy. We then assessed stage time...
<h3>Importance</h3> Patients with autoimmune disease and lung cancer pose a multidisciplinary treatment challenge, particularly the advent of immunotherapy. However, association between survival is largely unknown. <h3>Objective</h3> To determine survival. <h3>Design, Setting, Participants</h3> Retrospective cohort study 2003 2019 at single academic medical center (Northwestern University). A query Northwestern Medicine Enterprise Data Warehouse identified 349 patients several diseases....
There have been numerous controversies surrounding cosmetic products and increased cancer risk. Such include associations between parabens breast cancer, hair dyes hematologic malignancies, talc powders ovarian cancer. Despite the prominent media coverage scientific investigations, majority of these currently lack conclusive evidence. In 2016, US Food Drug Administration (FDA) made publically available all adverse event reports in Center for Safety Applied Nutrition's Adverse Event Reporting...
To evaluate the efficacy of crofelemer, a first in class anti-secretory anti-diarrheal agent, to manage neratinib-induced diarrhea patients with early-stage breast cancer taking adjuvant neratinib.This single center, open label trial enrolled Stage 2 3 HER2+ neratinib. One cohort took prophylactic crofelemer 125 mg bid and loperamide cycles, as needed subsequent cycles. The second dose-escalated neratinib (DE cohort). primary endpoint was incidence grade ≥ cycles.Seven 4 DE were enrolled. In...
Reversion mutations of somatic BRCA are an important source resistance within ovarian cancer. Furthermore, these reversion known to change over the course treatment. Better understanding mechanisms leading and role serial ctDNA collection in detecting changes overall landscape time is needed guide treatment metastatic setting.Here we study a case cancer undergoing multiple lines with three samples. These samples were analyzed by Guardant Health next generation sequencing detect alterations...
Early evaluation of tumor heterogeneity related to metastasis and outcomes is a major challenge in the management advanced breast cancer (BCa) clinic. In this study, we introduced value baseline circulating cells (CTC) ctDNA for early differentiation clinical stages, heterogeneity, prognosis
611 Background: Patient reported outcomes (PROs) capture direct feedback from patients in clinical trials. The NIH Patient-Reported Outcomes Measurement Information System (PROMIS) is an open source and validated PRO platform. Data on PROMIS score trajectories over time for breast cancer undergoing neoadjuvant chemotherapy (NAC) are limited. Methods: We administered paper surveys to enrolled the I-SPY2 trial, a multicenter, randomized phase 2 trial comparing novel agents standard NAC...
e24091 Background: Immune checkpoint inhibitors (ICI) have improved outcomes in patients with breast cancer, however management of immune-related adverse events (irAE) remains a challenge. Delayed irAE after cessation ICI been observed. We sought to characterize delayed occurring at our center. Methods: identified cancer who received UCSF using ICD codes specific administration between 2012-2018. After IRB approval, charts were reviewed for irAE. defined as >60 days the last dose; counted...
3036 Background: The presence of HER2 expressing (HER2+) circulating tumor cells (CTCs) occurs often in metastatic breast cancer (MBC) patients (pts). We have previously showed that the ratio among CTCs high level and total number HER2+ (circulating ratio, cHer2 ratio) has a prognostic role MBC patients. Here we further investigate cHER2 process spread. Methods: Under IRB-approved study prospectively analyzed blood samples with enrolled before starting new line therapy. Samples were...
Abstract Background: Immune checkpoint inhibitors (ICI) have improved outcomes in patients (pts) with breast cancer, however identification and management of immune-related adverse events (irAE) remains challenging. Delayed irAE been observed, occurring even after ICI cessation. Prior analyses delayed focused on melanoma, lung, head & neck cancer but data are lacking. Methods: We identified pts who received at our institution between 2012 2022 using pharmacy administration records....
Abstract Introduction: Interstitial Lung Disease (ILD) is a known adverse event associated with Antibody Drug Conjugates (ADCs), causing fibrosis of the lung. In DESTINY-Breast 04, TROPICS-02, and ASCENT trials rate ILD/Pneumonitis was 12.1%, 0.4%, 0% respectively. these studies, time to first cross-sectional imaging after initiation ADC 6 weeks. However, prior treatment topoisomerase-1 inhibitor not permitted in so influence sequential treatments remains unknown. Here, we aimed characterize...
<title>Abstract</title> Purpose Establishing breast MRI imaging patterns associated with neoadjuvant immunotherapy is needed to monitor response. We analyzed serial MRIs in patients receiving chemo-immunotherapy on the ISPY-2 clinical trial. Methods Patients had stage 2–3 HER2-negative cancer a single institution. Regimens included: weekly paclitaxel (control), combination pembrolizumab, or pembrolizumab and intra-tumoral injection of SD-101, TLR9 agonist. All then received AC underwent...
<p>Details for Figure 4A</p>